NOVARTIS

Zykadia-noxalk

“Zykadia” contains Drug / Molecule called “Ceritinib”. Zykadia is an anaplastic lymphoma kinase (ALK) positive inhibitor primarily used for the treatment of metastatic NSCLC. Zykadia thus acts to inhibit mutated enzyme and stop cell proliferation, ultimately halting cancer progression.

“Noxalk” is the generic version of “Zykadia” and both contains same drug “Ceritinib”.

Details
Specification

Indication

Zykadia is used for the treatment of non-small cell lung cancer.

Note

Precaution

Zykadia is a prescription drug and should be used under proper medical guidance and advice.
Zykadia may cause severe, life-threatening or fatal interstitial lung disease / pneumonitis.

Updated On Nov 01, 2019 by Admin

Strength

150 mg

Packing

1 X 10 Capsules (Strip)

Storage

Store at room temperature (25°C).

Was this page helpful?

☆ ☆ ☆ ☆ ☆

Not Upto Date Insufficient Helpful

Any suggestions or inputs for Shubhampharma.

Zykadia-noxalk also available as

NATCO PHARMA LIMITED (INDIA)

Noxalk

"Noxalk" contains Drug / Molecule called "Ceritinib". Noxalk is an anaplastic lymphoma kinase (ALK) positive inhibitor primarily used for the treatment of metastatic NSCLC. Noxalk thus acts to inhibit mutated enzyme and stop cell proliferation, ultimately halting cancer progression.